Azael Freites-Martinez1, Bernice Y Kwong2, Kerri E Rieger3, Daniel G Coit4, A Dimitrios Colevas5, Mario E Lacouture1. 1. Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 2. Department of Dermatology, Stanford University School of Medicine, Stanford, California. 3. Department of Pathology and Dermatology, Stanford University School of Medicine, Stanford, California. 4. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. 5. Department of Head and Neck Surgery, Stanford University Medical Center, Stanford, California.
Abstract
Importance: To our knowledge, there have been no previous reports of eruptive keratoacanthomas (KAs) in patients receiving pembrolizumab. Objective: To report the cases of 3 consecutive patients with pembrolizumab-induced eruptive KAs and their management. Design, Setting, and Participants: Case report study of 3 patients from 2 centers with pembrolizumab-treated cancer who all developed eruptive KAs. Interventions: All 3 patients had AK treatment with clobetasol ointment and intralesional triamcinolone; 2 patients also underwent open superficial cryosurgery. Results: Three consecutive patients with cancer, 2 men and 1 woman (median age, 83 years; range 77-91 years), experienced pembrolizumab-associated eruptive KAs. All patients presented with a sudden onset of multiple lesions on sun-exposed areas of their extremities after a median of 13 months (range, 4-18 months) of pembrolizumab therapy. On lesional biopsy, a lichenoid infiltrate was observed in the underlying dermis, predominantly composed of CD3+ T cells, scattered CD20+ B cells, and relatively few PD-1+ (programmed cell death 1-positive) T cells, an immunophenotypic pattern also observed in other cases of anti-PD-1-induced lichenoid dermatitis. Patients were treated with clobetasol ointment and intralesional triamcinolone, alone or in combination with open superficial cryosurgery. All KAs resolved in all patients, and no new lesions occurred during close follow-up. Pembrolizumab treatment was continued without disruption in all 3 cases, and all patients had complete responses of their primary cancers. Conclusions and Relevance: Pembrolizumab is used in advanced melanoma, advanced non-small-cell lung cancer, and in head and neck cancer. A variety of dermatologic immune-related adverse events including maculopapular eruption, lichenoid reactions, pruritus, and vitiligo have been described. This case series demonstrates that pembrolizumab therapy may also be associated with eruptive KAs with characteristic dermal inflammation, which improved with corticosteroid treatment (topical and intralesional) alone or in combination with cryosurgery, allowing patients to continue therapy with pembrolizumab.
Importance: To our knowledge, there have been no previous reports of eruptive keratoacanthomas (KAs) in patients receiving pembrolizumab. Objective: To report the cases of 3 consecutive patients with pembrolizumab-induced eruptive KAs and their management. Design, Setting, and Participants: Case report study of 3 patients from 2 centers with pembrolizumab-treated cancer who all developed eruptive KAs. Interventions: All 3patients had AK treatment with clobetasol ointment and intralesional triamcinolone; 2 patients also underwent open superficial cryosurgery. Results: Three consecutive patients with cancer, 2 men and 1 woman (median age, 83 years; range 77-91 years), experienced pembrolizumab-associated eruptive KAs. All patients presented with a sudden onset of multiple lesions on sun-exposed areas of their extremities after a median of 13 months (range, 4-18 months) of pembrolizumab therapy. On lesional biopsy, a lichenoid infiltrate was observed in the underlying dermis, predominantly composed of CD3+ T cells, scattered CD20+ B cells, and relatively few PD-1+ (programmed cell death 1-positive) T cells, an immunophenotypic pattern also observed in other cases of anti-PD-1-induced lichenoid dermatitis. Patients were treated with clobetasol ointment and intralesional triamcinolone, alone or in combination with open superficial cryosurgery. All KAs resolved in all patients, and no new lesions occurred during close follow-up. Pembrolizumab treatment was continued without disruption in all 3 cases, and all patients had complete responses of their primary cancers. Conclusions and Relevance: Pembrolizumab is used in advanced melanoma, advanced non-small-cell lung cancer, and in head and neck cancer. A variety of dermatologic immune-related adverse events including maculopapular eruption, lichenoid reactions, pruritus, and vitiligo have been described. This case series demonstrates that pembrolizumab therapy may also be associated with eruptive KAs with characteristic dermal inflammation, which improved with corticosteroid treatment (topical and intralesional) alone or in combination with cryosurgery, allowing patients to continue therapy with pembrolizumab.
Authors: Shelley Ji Eun Hwang; Giuliana Carlos; Deepal Wakade; Karen Byth; Benjamin Y Kong; Shaun Chou; Matteo S Carlino; Richard Kefford; Pablo Fernandez-Penas Journal: J Am Acad Dermatol Date: 2016-01-12 Impact factor: 11.527
Authors: Veronica J Shi; Nemanja Rodic; Scott Gettinger; Jonathan S Leventhal; Julia P Neckman; Michael Girardi; Marcus Bosenberg; Jennifer N Choi Journal: JAMA Dermatol Date: 2016-10-01 Impact factor: 10.282
Authors: Mario E Lacouture; John C Morris; Donald P Lawrence; Antoinette R Tan; Thomas E Olencki; Geoffrey I Shapiro; Bruce J Dezube; Jay A Berzofsky; Frank J Hsu; Joan Guitart Journal: Cancer Immunol Immunother Date: 2015-01-13 Impact factor: 6.968
Authors: Sumaira Aasi; Rona Silkiss; Jean Y Tang; Ashley Wysong; Andy Liu; Ervin Epstein; Anthony E Oro; Anne Lynn S Chang Journal: JAMA Dermatol Date: 2013-02 Impact factor: 10.282
Authors: Richard W Joseph; Mark Cappel; Brent Goedjen; Matthew Gordon; Brandon Kirsch; Cheryl Gilstrap; Sanjay Bagaria; Anokhi Jambusaria-Pahlajani Journal: Cancer Immunol Res Date: 2014-10-06 Impact factor: 11.151
Authors: Charles Kyung Min Lee; Shufeng Li; Duy Cong Tran; Gefei Alex Zhu; Jinah Kim; Bernice Y Kwong; Anne Lynn S Chang Journal: J Am Acad Dermatol Date: 2018-05-29 Impact factor: 11.527
Authors: A Boada; C Carrera; S Segura; H Collgros; P Pasquali; D Bodet; S Puig; J Malvehy Journal: Clin Transl Oncol Date: 2018-05-24 Impact factor: 3.405
Authors: Samantha R Ellis; Aren T Vierra; Jillian W Millsop; Mario E Lacouture; Maija Kiuru Journal: J Am Acad Dermatol Date: 2020-04-29 Impact factor: 11.527
Authors: Rachel L Marsh; Joanna A Kolodney; Sanjana Iyengar; Ahmed Yousaf; B Asher Louden; Abdullah Al-Bouri; Michael S Kolodney Journal: JAAD Case Rep Date: 2020-04-29
Authors: Regina Havenith; Luka de Vos; Anne Fröhlich; Christine Braegelmann; Judith Sirokay; Jennifer Landsberg; Joerg Wenzel; Thomas Bieber; Dennis Niebel Journal: Dermatol Ther (Heidelb) Date: 2021-02-23